BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx...
...proposed to sell 4.7 million shares at $20-$23. Harmony markets Wakix pitolisant to treat excessive daytime sleepiness.Inhibrx Inc....
...valuation of $756.2 million. The biotech sold 7 million shares at $17, raising $119 million. Inhibrx...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...out Qiagen”).Inhibrx, Harmony near NASDAQ IPOsA pair of companies have set terms this week for their proposed IPOs.Inhibrx Inc....
...on T cell responses to COVID-19. BC Staff Nurtec ODT, rimegepant (BHV-3000, bms-927711) Zavegepant (BHV-3500) Qiagen N.V. Thermo Fisher Scientific Inc. Inhibrx Inc. Harmony...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...23% stake in June (see “GSK-CureVac Deal Aims to Advance mRNA for Future Pandemics” ). Inhibrx Inc....
...$100 million. The biotech had initially filed for an IPO mid-2019, but withdrew in November. Inhibrx...
...Guanylate cyclase 2D membrane retina-specific BioCentury Staff Sanofi University of Florida Praxis Precision Medicines Inc. CureVac N.V. Harmony Biosciences Holdings Inc. Inhibrx Inc. Guanylate...
BioCentury | Dec 28, 2019
Financial News

Elpiscience’s $100M series B provides path to IPO

...testing for advanced solid tumors in China. Elpiscience gained China rights to ES101 (INBRX-105) from Inhibrx Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Biopharma Inc. 6/18/19 $4.6 Preclin Suzhou Zelgen Biopharmaceuticals Co. Ltd. (Shanghai) 6/10/19 TBD Ph III Inhibrx Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Mirum Pharmaceuticals Inc. 6/21/19 $75.0 Ph III Scopus Biopharma Inc. 6/18/19 Up to $4.5 Preclin Inhibrx Inc....
BioCentury | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

...diseases, and is also developing several new molecular entities. Inhibrx files for $75M NASDAQ IPO Inhibrx Inc....
...to $74.8 million in a NASDAQ IPO underwritten by Evercore, Barclays, Nomura and Raymond James. Inhibrx...
...including orphan and more prevalent autoimmune diseases and orphan oncology indications. BC Staff LTI-01 LTI-03 Hansoh Pharmaceutical Group Co. Ltd. Inhibrx Inc. Lung...
BioCentury | May 31, 2019
Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

...Innovent’s PD-1 mAb Tyvyt for Hodgkin Lymphoma" ). Inhibrx, Chiesi partner on rare disease candidate Inhibrx Inc....
...rights to develop and commercialize INBRX-101. Chiesi will make a $10 million equity investment in Inhibrx...
...million in upfront, profit sharing and milestone payments, plus royalties, if the option is exercised. Inhibrx...
BioCentury | May 30, 2019
Company News

May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

...tyrosine kinase 3; KLA - Klotho α Jonathan Block, Associate Editor Xospata, gilteritinib (ASP2215) Astellas Pharma Inc. Chiesi Farmaceutici S.p.A. Inhibrx Inc. Iovance...
BioCentury | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

...them to deliver standout returns" (see "What Woodford Worries?" ). Viking backs Inhibrx with $40M Inhibrx Inc....
...existing investors RA Capital, Lilly Asia Ventures, ArrowMark Partners, WuXi Biologics Inc. (HKSE:2269) and Alexandria. Inhibrx...
...a MAS receptor agonist in Phase IIb testing to treat sarcopenia. Chris Lieu, Staff Writer Biophytis S.A. Insmed Inc. Inhibrx Inc. Woodford...
Items per page:
1 - 10 of 26
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx...
...proposed to sell 4.7 million shares at $20-$23. Harmony markets Wakix pitolisant to treat excessive daytime sleepiness.Inhibrx Inc....
...valuation of $756.2 million. The biotech sold 7 million shares at $17, raising $119 million. Inhibrx...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...out Qiagen”).Inhibrx, Harmony near NASDAQ IPOsA pair of companies have set terms this week for their proposed IPOs.Inhibrx Inc....
...on T cell responses to COVID-19. BC Staff Nurtec ODT, rimegepant (BHV-3000, bms-927711) Zavegepant (BHV-3500) Qiagen N.V. Thermo Fisher Scientific Inc. Inhibrx Inc. Harmony...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...23% stake in June (see “GSK-CureVac Deal Aims to Advance mRNA for Future Pandemics” ). Inhibrx Inc....
...$100 million. The biotech had initially filed for an IPO mid-2019, but withdrew in November. Inhibrx...
...Guanylate cyclase 2D membrane retina-specific BioCentury Staff Sanofi University of Florida Praxis Precision Medicines Inc. CureVac N.V. Harmony Biosciences Holdings Inc. Inhibrx Inc. Guanylate...
BioCentury | Dec 28, 2019
Financial News

Elpiscience’s $100M series B provides path to IPO

...testing for advanced solid tumors in China. Elpiscience gained China rights to ES101 (INBRX-105) from Inhibrx Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Biopharma Inc. 6/18/19 $4.6 Preclin Suzhou Zelgen Biopharmaceuticals Co. Ltd. (Shanghai) 6/10/19 TBD Ph III Inhibrx Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Mirum Pharmaceuticals Inc. 6/21/19 $75.0 Ph III Scopus Biopharma Inc. 6/18/19 Up to $4.5 Preclin Inhibrx Inc....
BioCentury | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

...diseases, and is also developing several new molecular entities. Inhibrx files for $75M NASDAQ IPO Inhibrx Inc....
...to $74.8 million in a NASDAQ IPO underwritten by Evercore, Barclays, Nomura and Raymond James. Inhibrx...
...including orphan and more prevalent autoimmune diseases and orphan oncology indications. BC Staff LTI-01 LTI-03 Hansoh Pharmaceutical Group Co. Ltd. Inhibrx Inc. Lung...
BioCentury | May 31, 2019
Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

...Innovent’s PD-1 mAb Tyvyt for Hodgkin Lymphoma" ). Inhibrx, Chiesi partner on rare disease candidate Inhibrx Inc....
...rights to develop and commercialize INBRX-101. Chiesi will make a $10 million equity investment in Inhibrx...
...million in upfront, profit sharing and milestone payments, plus royalties, if the option is exercised. Inhibrx...
BioCentury | May 30, 2019
Company News

May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

...tyrosine kinase 3; KLA - Klotho α Jonathan Block, Associate Editor Xospata, gilteritinib (ASP2215) Astellas Pharma Inc. Chiesi Farmaceutici S.p.A. Inhibrx Inc. Iovance...
BioCentury | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

...them to deliver standout returns" (see "What Woodford Worries?" ). Viking backs Inhibrx with $40M Inhibrx Inc....
...existing investors RA Capital, Lilly Asia Ventures, ArrowMark Partners, WuXi Biologics Inc. (HKSE:2269) and Alexandria. Inhibrx...
...a MAS receptor agonist in Phase IIb testing to treat sarcopenia. Chris Lieu, Staff Writer Biophytis S.A. Insmed Inc. Inhibrx Inc. Woodford...
Items per page:
1 - 10 of 26